Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

Documenti analoghi

• Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
  di: Mamounas, Eleftherios P., et al.
  Pubblicazione: (2010)
• Comparison of the Prognostic and Predictive Utilities of the 21-Gene Recurrence Score Assay and Adjuvant! for Women with Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
  di: Tang, Gong, et al.
  Pubblicazione: (2011)
• Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
  di: Wolmark, Norman, et al.
  Pubblicazione: (2016)
• 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
  di: Geyer, Charles E., et al.
  Pubblicazione: (2018)
• 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
  di: Mamounas, Eleftherios P., et al.
  Pubblicazione: (2017)